BOESS CARSTEN
SEC insider (Form 3/4/5 filer). CIK 0001277495. Director at ROCKET PHARMACEUTICALS, INC. (RCKT) and 2 other issuers. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 18, 2026. Located in CRANBURY, NJ.
Companies BOESS CARSTEN has filed insider reports for
- ROCKET PHARMACEUTICALS, INC. (RCKT): Director
- Atrium Therapeutics, Inc. (RNA): Director
- Avidity Biosciences, Inc. (RNAM): Director
BOESS CARSTEN
CIK: 0001277495
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)4 (80.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (20.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 18, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
AwardDirect22.9K shares- - Feb 27, 2026RNA
Atrium Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
20K shares- - Feb 27, 2026RNAM
Avidity Biosciences, Inc.
DispositionDirect6.7K shares- - Jun 18, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
AwardDirect30K shares- - Jun 10, 2025RNA
Avidity Biosciences, Inc.
AwardDirect6.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  RCKT ROCKET PHARMACEUTICALS, INC. | Award | 22,862 | - | $0 | Direct |
| Feb 27, 2026 |  RNA Atrium Therapeutics, Inc. | Award Stock Option (Right to Buy) | 20,000 | - | - | Direct |
| Feb 27, 2026 |  RNAM Avidity Biosciences, Inc. | Disposition | 6,692 | - | $0 | Direct |
| Jun 18, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Award | 30,000 | - | - | Direct |
| Jun 10, 2025 | RNA Avidity Biosciences, Inc. | Award | 6,692 | - | - | Direct |
1-5 of 5 transactions